Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

NK Cell Therapy for Cancer Prevention: What High-Risk Patients Should Know

Written by Dr. David Greene, MD, PhD, MBA on July 13, 2026

Table of Contents

If a close relative has had cancer, a genetic test showing a hereditary risk marker can be unsettling news. For many patients, that uncertainty leads to a natural question: is there anything proactive I can do beyond waiting and watching?

One option that comes up in conversations about regenerative and cellular medicine is natural killer (NK) cell therapy — a form of immune cell therapy that has an established, growing role in treating certain cancers and is now being explored, more speculatively, as a preventive option for people who carry elevated genetic risk. This article looks at what NK cells actually do, what the research does and does not support about using them preventively, and how this option fits alongside long-established medical approaches to hereditary cancer risk.

What Are NK Cells, and What Do They Do?

Natural killer cells are a type of white blood cell belonging to the innate immune system — the body’s first line of defense, separate from the antibody-driven adaptive immune response. Unlike T cells, NK cells don’t need to be “trained” to recognize a specific threat first. Instead, they patrol the body and target cells that look abnormal, including virus-infected cells and cells that have undergone early cancerous changes, largely by detecting the absence of normal identifying markers on a cell’s surface (sometimes called the “missing-self” mechanism). This immune-surveillance role is part of a broader picture of how cell-based therapies interact with immune system function more generally.

This surveillance role is what researchers refer to as cancer immunosurveillance: the ongoing process by which the immune system identifies and eliminates abnormal cells before they can develop into a tumor.

The Evidence Behind NK Cells and Cancer Risk

The idea that NK cell activity matters for cancer outcomes isn’t new, and it isn’t fringe. It’s an active area of academic cancer immunology research.

A long-running population study that tracked NK cell cytotoxicity in thousands of people over an 11-year follow-up period found that individuals with higher baseline NK cell activity had a lower incidence of cancer, while those with lower activity had a higher incidence — one of the more frequently cited pieces of evidence for a real-world link between NK cell function and cancer risk. Subsequent research in specific cancer types, including colorectal cancer, has found a similar inverse relationship between NK cell cytotoxicity and cancer incidence in high-risk populations, along with associations between stronger NK cell function and better survival outcomes in people already diagnosed with cancer.

This is meaningful evidence that NK cell function is a marker of, and likely a contributor to, cancer risk at a population level. It is a different claim, however, to say that infusing additional NK cells into a healthy person will lower their individual risk of developing cancer — that specific application has far less direct clinical trial support, and is best understood as an extension of the immunosurveillance concept rather than a proven intervention in its own right.

Genetic Cancer Risk: Where NK Cell Therapy Fits Today

For people who learn through genetic testing that they carry a hereditary cancer risk — a BRCA1 or BRCA2 mutation being the best-studied example — there is an established set of medical options with substantial clinical evidence behind them:

Strategy

What It Involves

Evidence Level

Enhanced screening

More frequent mammograms, breast MRI, or other imaging based on risk

Well established; improves early detection

Risk-reducing surgery

Prophylactic mastectomy and/or salpingo-oophorectomy

Strong evidence; associated with substantial reductions in cancer incidence and mortality, particularly in BRCA1 carriers

Chemoprevention

Medications such as tamoxifen or raloxifene

Established option; associated with meaningful reductions in breast cancer incidence in high-risk individuals

NK cell / immune cell therapy

Testing and, in some cases, expanding a patient’s own NK cells

Early-stage and largely investigational for prevention; stronger evidence exists for NK cell therapy as a cancer treatment than as a preventive measure

This is an important distinction for patients to understand. Surgical and pharmacological risk-reduction strategies for confirmed hereditary mutations are backed by large studies and formal clinical guidelines. NK cell therapy as a preventive strategy for healthy, high-risk individuals has biological plausibility and encouraging correlational data, but it has not been established through the same level of rigorous, controlled clinical trials. Patients with a confirmed hereditary cancer syndrome should treat NK cell therapy as a possible complement to guideline-recommended care, discussed with their treating physician or genetic counselor — not a substitute for it.

Testing and Expanding Your Own NK Cells: Why Health Status Matters

One practical point raised by clinicians who work in this space is that not everyone is an equally good candidate for autologous NK cell therapy — therapy using a patient’s own cells rather than donor (allogeneic) cells. The broader tradeoffs between using a patient’s own cells versus donor-derived cells are a recurring theme across regenerative and cellular medicine, not just NK cell therapy specifically.

Before considering expansion or infusion, a patient’s existing NK cell count and cytotoxic activity can be tested. This matters because autologous NK cells are generally more difficult to culture successfully in patients who have already gone through intensive chemotherapy or radiation, since those treatments can weaken or reduce the quality of a patient’s own lymphocyte population, including NK cells. For someone who is otherwise healthy — for example, someone pursuing this proactively because of family history rather than because they’ve already been treated for cancer — collecting and expanding their own NK cells is generally more straightforward from a lab standpoint.

This is also part of why interest in immune cell banking and monitoring has grown in parts of Asia, where NK cell testing and expansion services are more widely available as part of general wellness and preventive health offerings, separate from formal cancer treatment. It’s worth noting this reflects consumer demand and regional availability more than a global clinical consensus on preventive efficacy.

Safety Profile of NK Cell Infusions

Safety data on NK cell therapy comes primarily from clinical trials in cancer patients, since that is where the majority of research has been conducted. Across multiple early-phase trials — including studies using expanded autologous NK cells and studies using the NK-92 cell line — treatment has generally been described as well tolerated, with toxicities mostly limited to short-term infusion-related reactions such as fever, chills, nausea, and fatigue. Serious adverse events have been comparatively rare in these trials, though at least one study identified an unexpected signal (a cluster of herpes zoster cases) worth continued monitoring, underscoring that even a “well tolerated” therapy in early trials still warrants careful medical supervision rather than casual use.

It’s reasonable to describe the treatment’s known side-effect profile, in the settings it has been studied, as mild to moderate. It is not yet possible to say with confidence what the safety profile looks like specifically in large numbers of healthy people using it purely for prevention, since that population hasn’t been studied to the same extent as cancer patients.

The Emotional Weight of Hereditary Cancer Risk

Learning that you carry a genetic marker associated with a parent’s or grandparent’s cancer diagnosis can understandably weigh on a person. Feeling that you’re doing something proactive — whether that’s enhanced screening, a preventive medication, or exploring emerging options like immune cell therapy — can be a meaningful part of managing that uncertainty, alongside supportive care and open conversations with a genetic counselor or physician about what the evidence actually supports for your specific mutation and risk level.

Where This Leaves Patients Considering NK Cell Therapy

Clinics offering regenerative and cellular medicine services, including R3 Stem Cell, have incorporated NK cell testing and autologous NK cell therapy into their offerings, often for patients interested in a proactive approach to immune health alongside — not instead of — standard medical care. For a patient exploring this path, it helps to work through the same questions worth asking before undergoing any regenerative procedure, including:

Has my NK cell count and cytotoxic activity actually been tested, or is expansion being recommended without baseline testing?

If I have a confirmed genetic mutation, am I still following the screening and risk-reduction guidelines recommended for that mutation?

What does the clinic's data show about outcomes specifically in a preventive, non-cancer-treatment context, versus cancer-treatment contexts?

Is my care team communicating with my oncologist or genetic counselor, if I have one?

Conclusion

NK cells are a genuine and well-studied part of the body’s defense against cancer, and there is real scientific interest in whether boosting their number or activity could help people at elevated genetic risk. At the same time, the strongest evidence for preventing cancer in someone with a confirmed hereditary risk still points to established options like enhanced screening, risk-reducing surgery, and chemoprevention. NK cell therapy is best understood today as one part of a broader, evolving field of regenerative medicine and immune health support — one worth discussing with a qualified physician alongside, not in place of, guideline-based hereditary cancer care.

Contact Us